Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 18 of 29 for:    Pulmonary Hypertension OR Vascular dementia OR Vascular Dementia OR Vascular Contributions to Cognitive Impairment and Dementia | Recruiting, Not yet recruiting, Available Studies | NIH, U.S. Fed

Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04125745
Recruitment Status : Recruiting
First Posted : October 14, 2019
Last Update Posted : November 13, 2019
Sponsor:
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
Complexa, Inc.
Information provided by (Responsible Party):
Marc A. Simon, University of Pittsburgh

Brief Summary:
The main objective of this study is to evaluate the safety and tolerability of 12-week oral CXA-10 therapy in subjects with pulmonary arterial hypertension, with additional evaluation on the clinical efficacy of oral CXA-10 on changes in hemodynamics, exercise capacity, cardiovascular function and patient reported outcomes.

Condition or disease Intervention/treatment Phase
Pulmonary Arterial Hypertension Drug: CXA-10 Phase 2

Detailed Description:

This is a single-center, one-arm, open-label proof of concept safety study and a phase 2a proof of efficacy pre- and post-assessment study of oral CXA-10 for the treatment of pulmonary arterial hypertension.

The investigators hypothesize that administration of CXA-10 for 12 weeks will improves exercise capacity, cardiovascular function and health related quality of life in pulmonary arterial hypertension patients with limited toxicity.

Subjects who meet the inclusion criteria and none of the exclusion criteria will be scheduled within 4 weeks of screening to receive oral CXA-10 at the dose of 150 mg once daily followed by 12 weeks of open-label CXA-10 treatment and then a 4-week safety follow-up. Additional follow-up assessments by telephone will occur in between each outpatient clinic visit.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Intervention Model Description: One-arm, open-label
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Open-Label Study of Safety and Efficacy Trial of CXA-10 in Pulmonary Arterial Hypertension
Actual Study Start Date : October 31, 2019
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : December 31, 2023


Arm Intervention/treatment
Experimental: CXA-10
Oral CXA-10 150mg once daily for 12 weeks
Drug: CXA-10
Each subject will receive oral CXA-10 at the dose of 150 mg once daily for 12 weeks
Other Name: 10-nitro-9(E)-octadec-9-enoic acid




Primary Outcome Measures :
  1. Number of Treatment-Related Adverse Events as assessed by CTCAE v4.0 in 12 Weeks [ Time Frame: Baseline to 12 Weeks ]
    Numbers of treatment-related adverse events is assessed by CTCAE v4.0


Secondary Outcome Measures :
  1. Change from Baseline in Pulmonary Vascular Resistance is measured at baseline and 12 weeks by Right Heart Catheterization [ Time Frame: Baseline and 12 Weeks ]
    Pulmonary vascular resistance will be measured by right heart catheterization

  2. Change from Baseline in Mean Pulmonary Artery Pressure is measured at baseline and 12 weeks by Right Heart Catheterization [ Time Frame: Baseline and 12 Weeks ]
    Pulmonary Artery mean pressure will be measured by right heart catheterization

  3. Change from baseline in RV function as measured by tricuspid annular plane systolic excursion (TAPSE) as assessed by echocardiograms at 12 weeks [ Time Frame: at baseline and 12 weeks ]
    Change from baseline in RV function as measured by tricuspid annular plane systolic excursion (TAPSE) as assessed by echocardiograms at 12 weeks

  4. Changes from baseline in functional exercise capacity by assessing 6 minute walk distance test [ Time Frame: at baseline and 12 weeks ]
    Change from baseline in 6 minute walk distance at 12 weeks

  5. Change from Baseline in levels of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) at 12 Weeks [ Time Frame: at Baseline and 12 Weeks ]
    Blood samples will be collected for NT-proBNP analysis

  6. Change from Baseline in Functional Status of Patients as Assessed by New York Heart Association Functional Class [ Time Frame: at Baseline and 12 Weeks ]
    The New York Heart Association Classification of Functional Status of Patients with pulmonary hypertension will be used to classify disease severity in PAH. It places patients in one of four categories based on how much they are limited during physical activity.

  7. Change from Baseline in Daily Physical Activity as Measured by a Accelerometer [ Time Frame: Baseline and 12 Weeks ]
    Continuous physical activity monitoring will be conducted using a noninvasive accelerometer. The device must be worn for a minimum of 7 days at home prior to receiving the first dose of the study drug and prior to the end of the study drug treatment at week 12.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female between 18-80 years of age inclusive at screening
  • Weight ≥ 40 kg or 88 lbs.
  • Have a WHO Classification of Functional Status Class II or III
  • Must meet all of the hemodynamic criteria by means of a right heart catheterization: mPAP of ≥25 mmHg, PVR ≥ 3 wood units, PAWP of ≤15 mmHg. A clinical RHC done within 2 months may be acceptable to determined eligibility.
  • Meet all of the following pulmonary function test parameters, completed no more than 12 months before Screening or at screening: forced expiratory volume in one second (FEV1) > 60% of predicted normal and forced vital capacity (FVC) ≥ 60%
  • A 6 MWD test of ≥ 100 m and ≤ 600 m at Screening
  • Participants enrolled in an exercise program for pulmonary rehabilitation must be in a stable program 1 month prior to Screening and must agree to maintain their current level of rehabilitation throughout the study. If subjects are not enrolled in an exercise training program for pulmonary rehabilitation they cannot enroll during the screening/baseline period or throughout the study
  • If receiving 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (i.e., statins) subjects must not have changed their dose <4 weeks prior to Screening.
  • If receiving simvastatin-containing products, the subject's simvastatin dose should not exceed 20 mg/day.
  • If receiving simvastatin-containing products: simvastatin (Zocor), Vytorin, or any other combination therapy containing simvastatin, the subject's simvastatin dose should not exceed 20 mg/day. Note: Subjects using a simvastatin product at dose > 20 mg/day may be rescreened if their dose has been adjusted to < 20 mg/day, at least 4 weeks prior to Screening with no dose or regimen changes within 4 weeks prior to Baseline
  • Subjects must be receiving one or more of the following previously approved PAH therapies: phosphodiesterase type 5 inhibitors (PDE5), endothelin receptor antagonist (ERA), soluble guanylate cyclase (sGC) stimulator, prostanoids, prostacyclin receptor agonists and must be on stable doses (> 3 months) with no dose adjustment within 1 month of Screening
  • Ability to provide written informed consent

Exclusion Criteria:

  • Portopulmonary hypertension and pulmonary veno-occlusive diseases.
  • Congenital heart defects (i.e., atrial septal defects, ventricular septal defects, and patent ductus arteriosus) repaired less than 1 year prior to Screening (Group 1 classification of Pulmonary Hypertension)
  • Systolic blood pressure > 160 or < 90 mmHg or diastolic blood pressure > 110 mmHg at Screening
  • QTc interval of >500 msec on Electrocardiogram at Screening
  • Acute myocardial infarction or acute coronary syndrome (ST-Elevation Myocardial Infarction (STEMI), Non STEMI (NSTEMI) and or unstable angina) within the last 90 days prior to Screening
  • Recent cerebrovascular accident/transient ischemic attack (CVA/TIA) within the last 90 days prior to Screening
  • Recent hospitalization for left heart failure within the last 90 days prior to Screening
  • Clinically significant aortic or mitral valve disease defined as greater than moderate regurgitation or moderate stenosis; pericardial constriction; restrictive or constrictive cardiomyopathy; left ventricular dysfunction (LVEF < 50%); left ventricular outflow obstruction; symptomatic coronary artery disease; autonomic hypotension; or fluid depletion in the opinion of the investigator
  • Evidence of a life-threatening cardiac arrhythmias on ECG at Screening as determined by the physician investigator
  • Personal or family history of congenital prolonged QTc syndrome or sudden unexpected death due to a cardiac reason
  • Receiving intravenous inotropes (e.g. dopamine, dobutamine) within 2 weeks prior to Screening
  • History of angina pectoris or other condition that was treated with long or short acting nitrates <12 weeks of Screening
  • History of herbal or natural medication use (including fish oil) within 2 weeks or 5 half-lives, whichever is longer, prior to Baseline
  • Subject has taken prednisone at doses > 15 mg/day; if immunosuppressive medications are used the dose must be stable within 12 weeks prior to Screening and throughout the study
  • The subject is currently taking a drug that may affect the assay measurement of serum creatinine (e.g. cimetidine, Bactrim, Pyridium)
  • Newly prescribed drug or increased dose of an existing drug that is known to prolong the QTc interval and has been associated with Torsades de Pointes Note: Stable doses of these drugs are permitted (i.e., subject has received the same dose and regimen for at least 30 days prior to Screening with no anticipated changes to the dose or regimen during the course of the study)
  • The subject is currently taking dimethyl fumarate (Tecfidera™)
  • Females with a positive urine pregnancy test at Screening or prior to dosing or who are pregnant or breastfeeding or who are trying to conceive
  • Recent (within 6 months) history of abusing alcohol or illicit drugs
  • History of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, with the exception of basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ or other malignancies curatively treated and with no evidence of disease for at least 5 years or prostate cancer who is not currently or expected, during the study, to undergo radiation therapy, chemotherapy, and/or surgical intervention, or to initiate hormonal treatment
  • Cardiovascular, liver, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, central nervous system or psychiatric disease that, in the opinion of the investigator, may adversely affect the safety of the subject and/or efficacy of the investigational product or severely limit the lifespan of the subject other than the condition being studied
  • Clinically significant hyperthyroidism or hypothyroidism not adequately treated
  • Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)
  • The subject has known hypersensitivity to the CXA-10, the metabolites, or formulation excipients
  • The subject has had treatment with any investigational drug within 30 days or 5 half-lives (whichever is longer) prior to Screening or plans to participate in an investigational drug study at any time during this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04125745


Contacts
Layout table for location contacts
Contact: Nicole Helbling, DNP, RN, CRNP 412-692-2285 nlr8@pitt.edu

Locations
Layout table for location information
United States, Pennsylvania
University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Nicole L Helbling, DNP, RN, CRNP    4126922285    nlr8@pitt.edu   
Sponsors and Collaborators
Gladwin, Mark, MD
National Heart, Lung, and Blood Institute (NHLBI)
Complexa, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Marc Simon, MD University of Pittsburgh

Layout table for additonal information
Responsible Party: Marc A. Simon, Associate Professor of Medicine, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT04125745     History of Changes
Other Study ID Numbers: STUDY19010004
P01HL103455 ( U.S. NIH Grant/Contract )
First Posted: October 14, 2019    Key Record Dates
Last Update Posted: November 13, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The PI will make individual participant data (IPD) available through a data sharing agreement. After publication, data will be deposited in all available suitable public access databases for archival purposes.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: Starting 6 months after publication
Access Criteria: Through a data sharing agreement

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Familial Primary Pulmonary Hypertension
Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases